Basics CRISPR Therapeutics AG CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. IPO Date: October 19, 2016 Sector: Healthcare Industry: Biotech Market Cap: $3.27B Activated in VL: True Average Daily Range Avg Daily Range: $1.63 | 2.81% Avg Daily Range (30 D): $1.16 | 3.23% Avg Daily Range (90 D): $1.07 | 2.67% Institutional Daily Volume Avg Daily Volume: 1.1M Avg Daily Volume (30 D): 1.93M Avg Daily Volume (90 D): 1.96M Trade Size Avg Trade Size (Sh.): 64 Avg Trade Size (Sh.) (30 D): 63 Avg Trade Size (Sh.) (90 D): 65 Institutional Trades Total Inst.Trades: 5,187 Avg Inst. Trade: $2.73M Avg Inst. Trade (30 D): $2.51M Avg Inst. Trade (90 D): $2.3M Avg Inst. Trade Volume: .04M Avg Inst. Trades (Per Day): 3 Market Closing Trades Avg Closing Trade: $4.87M Avg Closing Trade (30 D): $5.45M Avg Closing Trade (90 D): $5.41M Avg Closing Volume: 72.98K         News Apr 20, 2025 @ 1:15 PM 5 Monster Stocks -- Such as Coupang -- to Hold for... Source: Selena Maranjian Apr 11, 2025 @ 7:45 AM Could CRISPR Therapeutics Become the Next Vertex P... Source: Adria Cimino Apr 8, 2025 @ 1:45 PM Is Vertex Pharmaceuticals Stock a Buy? Source: Dan Victor Apr 7, 2025 @ 12:09 PM 4 Beaten-Down Stocks That Could Skyrocket by 50% t... Source: Prosper Junior Bakiny Apr 7, 2025 @ 11:30 AM Cathie Wood Goes Bargain Hunting: 3 Stocks She Jus... Source: Rick Munarriz Financials   TTM Q4 2024 FY 2024 Basic EPS $-4.34 $-.42 $-4.34 Diluted EPS $-4.34 $-.42 $-4.34 Revenue $ 37.31M $ 35.69M $ 37.31M Gross Profit $ $ $ Net Income / Loss $ -366.25M $ -37.31M $ -366.25M Operating Income / Loss $ -466.57M $ -64.59M $ -466.57M Cost of Revenue $ $ $ Net Cash Flow $ -91.27M $ 72.67M $ -91.27M PE Ratio